After a first meeting in 2018, Médecins Sans Frontières, Sponsor of the endTB Clinical Trials, and its partners (PIH, IRD, HMS, ITM and Epicentre) have gathered for the second time the endTB Clinical Trial investigators and study coordinators in Paris. From the 10th to the 12th February 2020, 50 participants from countries involved in the trials, as well as members of the central team had the opportunity to discuss various aspects of endTB and share their experiences in the conduct of the clinical trial. In addition, during the meeting, a training was held for the implementation of the new clinical trial endTB-Q, which is expected to start enrolling MDR-TB patients with fluroquinolone resistance in March 2020.